Global Pegfilgrastim Biosimilars Market Report and Forecast 2023-2031

The global pegfilgrastim biosimilars market size was valued at USD 0.54 million in 2022 and is projected to grow at a CAGR of 7% during the forecast period of 2023-2031. The market growth can be attributed to the increasing prevalence of cancer, a growing geriatric population, and the rising demand for affordable cancer therapies.

Global Pegfilgrastim Biosimilars Market: Introduction

Pegfilgrastim biosimilars are biologically similar versions of the reference pegfilgrastim product, which is used to stimulate the growth of white blood cells to help reduce the risk of infection during cancer treatment. These biosimilars have demonstrated comparable safety and efficacy to the reference product but are typically available at a lower cost, making them an attractive option for healthcare systems and patients. The increasing prevalence of cancer, coupled with the growing demand for cost-effective cancer treatments, is driving the demand for pegfilgrastim biosimilars. Other factors, such as the expiration of key patents and the development of robust regulatory frameworks, are also expected to drive market growth.

Pegfilgrastim Biosimilars Market Segmentations

The market can be segmented based on indication, product type, application, distribution channel, and region:

Market Breakup by Indication Type

• Neutropenia
• Hematopoietic Subsyndrome
• Others

Market Breakup by Product Type

• MK-6302
• Peg G-CSF
• PEG Neutrogena
• Grasustek
• LA-EP2006
• R-TPR-029
• Filgrastim
• PEG-GCSF
• Others

Market Breakup by Application

• Chemotherapy Induced Neutropenia
• Transplantation
• Others

Market Breakup by Distribution Channel

• Hospital Based Pharmacies
• Online Pharmacies
• Retail Pharmacies

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Pegfilgrastim Biosimilars Market Analysis

The global pegfilgrastim biosimilars market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of cancer, the growing geriatric population, and the rising demand for cost-effective cancer therapies. North America is currently the largest market for pegfilgrastim biosimilars, driven by factors such as the high prevalence of cancer, a well-established healthcare infrastructure, and strong investments in research and development. Additionally, the growing adoption of biosimilars and supportive regulatory frameworks are further driving the growth of the market in North America.

Asia Pacific is another region experiencing significant growth in the pegfilgrastim biosimilars market. The region's market growth is driven by factors such as a large population base, increasing cancer incidence, and growing healthcare expenditure. In addition, government initiatives to improve healthcare infrastructure and support the development of biosimilars are helping to drive the growth of the market in the region.

Key Players in the Global Pegfilgrastim Biosimilars Market

The report provides a detailed analysis of the key players involved in the pegfilgrastim biosimilars market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

• Merck & Co., Inc
• Zydus Lifesciences Limited
• Ratiopharm GmbH
• Jiangsu Hengrui Pharmaceuticals Co. Ltd
• Biocon Limited
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Emcure Pharmaceuticals Limited
• USV Private Limited
• Apotex Pty Ltd
• Kyowa Kirin Co., Ltd
• Lupin Limited